Aquestive Therapeutics (AQST) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 10, 2026, at 9:30 AM ET, to be held virtually for shareholder participation.

• Shareholders are encouraged to review proxy materials and vote by June 9, 2026, via online platforms.

Voting matters and shareholder proposals

• Election of Gregory B. Brown, M.D., John S. Cochran, and Abigail L. Jenkins as Class II directors for three-year terms ending at the 2029 annual meeting.

• Advisory vote on executive compensation for named executive officers.

• Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.

• Provision to address any other matters that may arise during the meeting or its adjournment.

Board of directors and corporate governance

• Board recommends voting in favor of all director nominees and proposals.

• Director nominees are proposed for staggered three-year terms to ensure continuity.